BioDelivery Sciences International has acquired the US and Canadian rights to ELYXYB from Dr. Reddy's Laboratories. ELYXYB is the only FDA-approved oral solution for the treatment of acute migraine. BioDelivery plans to begin selling ELYXYB in Q1 2022.